Quantcast
Last updated on April 20, 2014 at 5:20 EDT

NeuroDerm Announces Presentation of ND0612 Phase 1 and Phase 2 Results at the 2013 International Congress of Parkinson’s Disease and Movement Disorders

June 13, 2013

NESS ZIONA, Israel, June 13, 2013 /PRNewswire/ –

NeuroDerm, Ltd. today announced that abstracts reporting results from a phase I study
in healthy volunteers, and preliminary results from a phase IIA study in advanced
Parkinson’s patients, of ND0612, have been selected for presentation at the 17th
International Congress of Parkinson’s Disease and Movement Disorders, June 16th-20th in
Sydney, Australia.

ND0612 is a proprietary levodopa/carbidopa liquid drug formula under development for
continuous administration through a sub-cutaneous (SC) delivery patch that would maintain
constant levodopa plasma concentrations.

Details on the Presentations are as follows:

        Title: Constant Therapeutic Levodopa Plasma Concentrations Maintained by Continuous
         Subcutaneous Administration of ND-0612, a Novel Formulation of Levodopa/Carbidopa
        Abstract #: 452
        Presenter: Peter LeWitt
        Poster session: Parkinson's Disease: Clinical Trials
        Date and time: Tuesday, June 18th, 12:30pm
        Location: Bayside, level, 1 gallery B

        Title: ND0612, A Novel Formulation of Levodopa/Carbidopa for Continuous, Subcutaneous
         Administration, Achieves Steady-State Levodopa Plasma Concentrations in Parkinson's
         Disease Patients
        Abstract #: LBA26
        Presenter: Nir Giladi
        Poster session: Late Breaking Abstracts
        Date and time: Wednesday, June 19th, 12:00pm
        Location: Exhibit hall #5

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapies for the
treatment of CNS diseases. NeuroDerm’s technology is based on proprietary reformulations
of well-established oral drugs that achieve better efficacy. The company’s lead products
are ND0612, a novel sub-cutaneous drug formulation for the treatment of Parkinson’s
disease, and ND0801, a combination drug for the treatment of cognitive disorders in
diseases such as ADD/ADHD, schizophrenia and Alzheimer’s disease. NeuroDerm is
headquartered in the Weizmann Science Park, Ness Ziona, Israel.

        Contact:
        Oded S. Lieberman, PhD MBA, Chairman & CEO
        oded@neuroderm.com
        Tel.: +972-8-946 2729; Cell: +1-617-517-6077

SOURCE NeuroDerm Ltd


Source: PR Newswire